(PharmaNewsWire.Com, March 10, 2017 ) According to the report Asia-Pacific Cancer Monoclonal Antibodies Market, published by Market Data Forecast, the Asia-Pacific market is projected to reach USD 8.14 billion by 2020, at a CAGR of 13.5% from 2015 to 2020 Cancer is the cause of death for millions of people around the world. Cancer, which starts from a single cell, is gradually transformed to other cells by genetically transforming a normal cell to tumour. The dramatic increase in the size of cancer patients has made the pharmaceutical firms to shift their focus towards monoclonal antibodies market. The traditional way of treating cancer includes usage of drugs like chemotherapy agents which has adverse side effects. This persuaded the usage of monoclonal antibodies to treat cancer.
Recent years have seen the emergence of monoclonal antibodies market, offering less toxic and highly efficient therapeutics alternatives. The antibody agents are used to cure a wide array of diseases, especially cancer and autoimmune and inflammatory diseases. They are mono-specific antibodies having identical immune cells that are clone to the single parent cells and are directed to a specific target cell. This customizable feature of the antibodies due to its specific nature can play a critical role in eliminating the cancer cell while not affecting the healthy cells. Monoclonal antibodies are more effective in treating cancer than old methods like drugs or chemotherapy owing to their adverse side effects.
The drastic increase in the people affected by cancer prompted many pharmaceutical firms to invest in monoclonal antibodies. Rise in investment in R&D of genomic studies, monoclonal antibodies ability to target only specific cells, technological innovations in target gene selection and genetic sequencing, having no side effects compared to its counter parts are the primary drivers for the market. With the increased occurrence of cancer, the market is expected to grow significantly in the next 5 years having a presence of highly strong products in the pipeline. There are also few restraints for its market entry like stringent guidelines, high cost, long durations required for R&D, clinical trials.
The Cancer Monoclonal Antibodies Market is segmented as following: Based on Application: Liver Breast Brain Blood Hodgkins and Non-Hodgkins lymphoma Colorectal Leukaemia Others Based on Type: Murine Antibodies Chimeric and Humanised Antibodies Fully Humanized Antibodies Based on Conjugate Cancer Therapies: Immunoliposome Radioimmunotherapy ADEPT Immunocytokines Others
The major companies operating in the Asia-Pacific Cancer Monoclonal Antibodies Market are Amgen, Immunogen, Novartis, Bristol Myers Squibb, Roche, Genmab, glaxosmithkline, Seattle Genetics, Eli Lilly, and Spectrum Pharmaceuticals.
The Cancer Monoclonal Antibodies Market study offers the following deliverables: Asia-Pacific, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics Study of the effect of exogenous and endogenous factors that affect the Asia-Pacific market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis Study the micro environment factors that determine the overall profitability of an Industry, using Porters five forces analysis for analysing the level of competition and business strategy development A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Pharmaceuticals Segment:
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
